Fig. 3: A CCR2 inhibitor disrupts the protective effect of Mφs in vivo. | Cell Death & Disease

Fig. 3: A CCR2 inhibitor disrupts the protective effect of Mφs in vivo.

From: CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma

Fig. 3

a The workflow of the experiment in vivo. NSG mice were subcutaneously inoculated in the flank with 5 × 106 ARP-1 cells. When these mice bearing detectable tumors (Day 0), they were assigned randomly to five groups (n = 5 per group), with 0.4 × 105 Mφs injected into the tumor mass for two groups (Mφs + BTZ group, Mφs + CCX + BTZ group). Bortezomib (BTZ) was administered via intraperitoneal injection at a dose of 2 µg/mouse every 3 days. CCX140-B (CCX) was administered via oral gavage (500 µg/mouse) every day for 1 week, and tumor growth was monitored. b, c Graph showing the tumor volume at the end point of the trial. d Immunofluorescence analysis of CD138 (Red) and cleaved caspase-3 (Green) expression in tumor tissues from mice of different groups. Scale bar, 50 μm. Areal density of cleaved caspase-3 along intratumoral areas is represented on the right. Data show the mean ± SD of at least three mice per group. e Ratio of mRNA expression of the indicated M1 or M2 signature genes in CD14 + Mφs isolated from the tumor masses determined by RT-PCR. The data show means ± SD. NS not significant. *P < 0.05; **P < 0.01, ***P < 0.001

Back to article page